Engineered immune cells take aim at Hard-to-Treat KRAS cancers
NCT ID NCT07342738
First seen Jan 15, 2026 · Last updated May 19, 2026 · Updated 16 times
Summary
This early-phase study tests a new treatment called TCR-T, where a patient's own immune cells are modified in a lab to better recognize and attack cancer cells driven by KRAS mutations. The trial will enroll 25 adults with advanced solid tumors (such as colorectal or lung cancer) who have not responded to or cannot tolerate standard therapies. The main goals are to check the treatment's safety and see if it can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
Conditions
Explore the condition pages connected to this study.